Premenopausal Use of Progestogens and Cutaneous Melanoma Risk: A French Prospective Cohort Study.
The influence of sex hormones on melanoma risk has been suggested, but the influence of premenopausal use of progestogens on this cancer has never been investigated. E3N (Etude Epidémiologique auprès de femmes de l'Education Nationale) is a prospective cohort of 98,995 French women aged 40-65 years at inclusion. We used Cox models adjusted for age and melanoma risk factors. Over 1992-2008, 540 melanoma cases were ascertained among 79,558 women. We found a modest association between self-reported progestogen use and melanoma risk (Hazard Ratio (HR)=1.23; 95% confidence interval (CI)=1.02-1.47), which was reduced after adjustment for melanoma risk factors (HR=1.15; 95%CI=0.95-1.39). There was no heterogeneity across types of progestogens (P=0.22), and use of multiple progestogens was positively associated with melanoma risk (HR=1.33; 95%CI=1.04-1.70). Among users, we found no relation with duration of progestogen use, age at start and last use, and time since first and last use. Although our results did not show evidence of a confounding effect of sun exposure, progestogen users had lower levels of residential sun exposure and were more likely to report sunscreen use, suggesting specific sun exposure profiles in users. Our findings do not support a strong influence of progestogens on melanoma risk. Further research is needed to confirm these results.